Futura Medical PLC Publishes Fireside Chat with Prof Wayne Hellstrom
14 Noviembre 2019 - 1:01AM
RNS Non-Regulatory
TIDMFUM
Futura Medical PLC
14 November 2019
Futura Medical Publishes Fireside Chat with Professor Wayne
Hellstrom, member of the Futura Medical KOL Advisory Panel
14 November 2019
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a
pharmaceutical company developing a portfolio of innovative
products based on its proprietary, transdermal DermaSys(R) drug
delivery technology currently focused on sexual health and pain,
today publishes a fireside chat with Professor Wayne Hellstrom,
specialist in diagnosis and treatment of male sexual dysfunction
and a member of the Futura Medical Key Opinion Leader ("KOL")
Advisory Panel.
This follows Futura's third Scientific Advisory Meeting with
high profile US KOLs in the field of erectile dysfunction at the
20(th) Annual Fall Scientific Meeting of Sexual Medicine Society of
North America (SMSNA), on 24-27 October 2019 in Nashville,
Tennessee USA.
Professor Wayne Hellstrom spoke with Futura Medical's Executive
Director and Head of R&D, Ken James on the significant negative
effect ED has on the quality of life, relationships and overall
wellbeing of ED sufferers and their partners. The informal chat
also includes discussion on Futura's lead product MED2005, a
topical glyceryl trinitrate ("GTN") gel for the treatment of
erectile dysfunction ("ED").
A link to the fireside chat can be found here.
Dr. Wayne J.G. Hellstrom is Professor of Urology and Chief of
Andrology at Tulane University School of Medicine in New Orleans,
and Past President of the Sexual Medicine Society of North America
and the International Society of Sexual Medicine (ISSM).
James Barder, Chief Executive Officer of Futura Medical said:
"Futura held its third Advisory Board Panel meeting with leading
practitioners in urology and sexual medicine with a US focus at the
recent Annual SMSNA scientific meeting in Nashville, and once again
were very pleased to have received a positive reaction to the
therapeutic potential and differentiation of MED2005, reflecting
limited innovation in the past 20 years. As part of Futura's
educational programme to build awareness ahead of the Phase 3
results, we are very pleased to share our conversation with
prominent KOL Professor Hellstrom, on the significant negative
effect ED has on the quality of life, relationships and overall
wellbeing of ED sufferers and their partners. I would like to thank
Professor Hellstrom for his continued support.
We look forward to the Phase 3 data read out, which has made
excellent progress to date and is on track to deliver headline
efficacy and safety data in December this year, a key value
inflection point for the Company."
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal Dermasys(R) drug delivery technology.
These products are optimised for clinical efficacy, safety,
administration and patient convenience and are developed for the
prescription and consumer healthcare markets as appropriate.
Current therapeutic areas are sexual health, including erectile
dysfunction, and pain relief. Development and commercialisation
strategies are designed to maximise product differentiation and
value creation whilst minimising risk.
The first European Phase 3 study for MED2005, referred to as
"FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised,
double blind, placebo-controlled, home use, parallel group study of
MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment
of erectile dysfunction with an open label extension. FM57 is
progressing on track, with headline data expected by the end of
2019.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADMMMMVFZGLZM
(END) Dow Jones Newswires
November 14, 2019 02:01 ET (07:01 GMT)
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024